LifeMD (LFMD) Fundamental Analysis: Revenue, Earnings & Valuation

7.84 / 10

Outperform

Fundamentally, LFMD rates Outperform with a 7.8/10 rating. Cash‑to‑market and cash growth are strong, and revenue‑to‑market is positive. Weak points include inventory turnover and negative cash‑flow‑per‑share growth, tempering the otherwise promising profile.

Analysis Checks(6/10)

Revenue-MV

Value-1.41

Score3/3

Weight24.61%

1M Return6.67%

Net cash flow from operating activities per share (YoY growth rate %)

Value-57.25

Score0/3

Weight-5.37%

1M Return-2.26%

Inventory turnover ratio

Value9.95

Score1/3

Weight5.22%

1M Return1.74%

Net income-Revenue

Value2.57

Score0/3

Weight-6.30%

1M Return-2.25%

Basic earnings per share (YoY growth rate %)

Value141.67

Score3/3

Weight22.18%

1M Return6.64%

Total profit (YoY growth rate %)

Value54.88

Score3/3

Weight19.56%

1M Return5.90%

Net cash flow from operating activities (YoY growth rate %)

Value-52.72

Score1/3

Weight5.18%

1M Return1.69%

Cash-UP

Value-0.16

Score2/3

Weight3.54%

1M Return0.89%

Diluted earnings per share (YoY growth rate %)

Value141.67

Score3/3

Weight22.79%

1M Return6.86%

Cash-MV

Value0.03

Score2/3

Weight8.58%

1M Return2.77%

Is LFMD undervalued or overvalued?

LFMD scores 7.84/10 on fundamentals and holds a Discounted valuation at present. Backed by its 144.18% ROE, 8.05% net margin, 16.63 P/E ratio, 8.08 P/B ratio, and 141.67% earnings growth, these metrics solidify its Outperform investment rating.